ELTP Stock Updates 08/17/2014 06:22:50 $ELTP
Northvale, New Jersey, Friday, June 21, 2013:
Jerry Treppel, Chairman and CEO of Elite commented, "It has been a remarkable year for Elite. We launched new products, substantially increased our revenues, and lowered our operating losses. Most importantly, I can now tell you that we expect our first commercially scaled-up, abuse-resistant opioid product to enter human pilot studies later this year. We have also conducted work on another abuse-resistant opioid product. We have also received FDA feedback on clinical protocols for the extended release brompheniramine product and have filed a Citizen Petition regarding the extended release brompheniramine/pseudoephedrine product, which, if successful, would put this product in a position to also begin clinical trials and eventually secure approvals for bringing these products on to the market.
http://www.elitepharma.com/product_pipeline.asp
Brompheniramine
Maleate with
Pseudoephedrine HCl
24 hour product
Scale-up
Owned by Elite
That would make a lot of sense wouldn't it? You never know!
Pfizer has a string of recent "bad decision" acquisitions while currently facing several lawsuits. AstraZeneca decision to reject Pfizer's +$119 billion acquisition is how the industry now views Pfizer terrible reputation!
What new embeda trial? There was no such thing
Go far away
Why in the world would they buy elite?
Pfizer should just buy out ELTP! That would solve everyone's problems real quick!
Hardly scary as New Embeda trial helped ELI-200 successful BE/PK trials and is helping $ELTP pursuit of ELI-200 Commercial FDA approval.
As for Commercial New Embeda, if and when it does launch, will be highly unpredictable as to stability but beneficial to ELI-200 FDA accelerated approval and Physician preference as Camargo and $ELTP have postulated.
Oh by the way when did Purdue abandon that tech, link please lol lol
Oh by way still waiting on the elite patent information lol lol
Again complete misinformation. But as nasrat himself said, coming soon and that is really scary for us true longs lol lol
Hysterically funny alright. Pfizer/Alpharma/King + 4 yrs and several $million wasted engineering dollars still trying to modify a technology that Purdue wisely abandoned.
Perhaps a new designed extruder with less damaging heat/mechanical forces has been invented or perhaps Pfizer re-invents their patents? Who knows?
2nd Qtr 2014 new Embeda launch has failed and rumor is now 4th Qtr Oct 2014. Millions of dollars perhaps will buy Pizer something but then who would ever want to take an unpredictable new Embeda never knowing what will fail and cause serious dose dumping.
The simple answer is that they do not know, in fact Nasrat himself said very soon. It is clear that the reintroduction of Embeda is very very worrisome.
misinformation. First, they did not copy the Purdue technology and to say they did is a serious allegation, as it could result in treble damages. In fact, what occurred is that the companies settled, as they most often do, and that settlement makes it clear that Pfizer did not admit to any infringement. In addition, it is impossible for anyone except Pfizer to know what manufacturing process is used, as I have corrected the record here many many time, the patents refer to melt extrusion as but one example of manufacturing methods. Next.
LOL LOL serious breach of engineering principles??? LOL LOL hysterically funny. Elite (not even employing the inventor of their technology) and certainly not having any galenical though leaders is going to tech Pfizer how to do it correctly. LOL LOL This is so hysterically funny that I do not even know where to start. But hey. let me ask, how many patents does the CURRENT staff of this magical company have? That should be good for a few more laughs.
Unfortunately Pfizer no longer has their Elite Central Engineering staff that would have caught this serious breach of engineering principles before deciding to pay the $3.6 bil to acquire Alpharma/king. Pfizer with serious patent expirations has resorted these past 10 yrs to becoming an "acquisition" company thereby giving up "original discovery" new technology. Hundreds of key R&D personnel have been terminated.
It is sad to watch the proud Pfizer deteriorate. However when one picks an Accountant type to lead a Pharma the inevitable happens in terrible cost cutting decisions. "Penny wise Pound Foolish"
http://www.pfizer.com/about/leadership_and_st...an_c__read
Sounds like a bunch of loser companies.
Quote:
Pfizer/Alpharma/King
rfwelsh If you read my past posts on Purdue/Pfizer hot melt extrusion technology thru their patents that would help you to understand better. It is an extremely difficult engineering technology which Purdue never went forward with knowing that it would fail
Strangely Alpharma/King copied the original Purdue and were nailed by a Purdue lawsuit that forced Pfizer to pay royalties to Purdue.
Pfizer/Alpharma/King has already spent 4 years unsuccessfully to try and correct the heat and mechanical extrusion forces from seriously damaging the ER agonist polymer and the antagonist sequestering polymer which is the crux of the problem.
Because Nasrat didn't release the name of the valuation firm. But we will get to $2.10 eventually and even higher.
Northvale, New Jersey, Friday, June 21, 2013:
Jerry Treppel, Chairman and CEO of Elite commented, "It has been a remarkable year for Elite. We launched new products, substantially increased our revenues, and lowered our operating losses. Most importantly, I can now tell you that we expect our first commercially scaled-up, abuse-resistant opioid product to enter human pilot studies later this year. We have also conducted work on another abuse-resistant opioid product. We have also received FDA feedback on clinical protocols for the extended release brompheniramine product and have filed a Citizen Petition regarding the extended release brompheniramine/pseudoephedrine product, which, if successful, would put this product in a position to also begin clinical trials and eventually secure approvals for bringing these products on to the market.
http://www.elitepharma.com/product_pipeline.asp
Brompheniramine
Maleate with
Pseudoephedrine HCl
24 hour product
Scale-up
Owned by Elite
That would make a lot of sense wouldn't it? You never know!
Pfizer has a string of recent "bad decision" acquisitions while currently facing several lawsuits. AstraZeneca decision to reject Pfizer's +$119 billion acquisition is how the industry now views Pfizer terrible reputation!
What new embeda trial? There was no such thing
Go far away
Why in the world would they buy elite?
Pfizer should just buy out ELTP! That would solve everyone's problems real quick!
Hardly scary as New Embeda trial helped ELI-200 successful BE/PK trials and is helping $ELTP pursuit of ELI-200 Commercial FDA approval.
As for Commercial New Embeda, if and when it does launch, will be highly unpredictable as to stability but beneficial to ELI-200 FDA accelerated approval and Physician preference as Camargo and $ELTP have postulated.
Oh by the way when did Purdue abandon that tech, link please lol lol
Oh by way still waiting on the elite patent information lol lol
Again complete misinformation. But as nasrat himself said, coming soon and that is really scary for us true longs lol lol
Hysterically funny alright. Pfizer/Alpharma/King + 4 yrs and several $million wasted engineering dollars still trying to modify a technology that Purdue wisely abandoned.
Perhaps a new designed extruder with less damaging heat/mechanical forces has been invented or perhaps Pfizer re-invents their patents? Who knows?
2nd Qtr 2014 new Embeda launch has failed and rumor is now 4th Qtr Oct 2014. Millions of dollars perhaps will buy Pizer something but then who would ever want to take an unpredictable new Embeda never knowing what will fail and cause serious dose dumping.
The simple answer is that they do not know, in fact Nasrat himself said very soon. It is clear that the reintroduction of Embeda is very very worrisome.
misinformation. First, they did not copy the Purdue technology and to say they did is a serious allegation, as it could result in treble damages. In fact, what occurred is that the companies settled, as they most often do, and that settlement makes it clear that Pfizer did not admit to any infringement. In addition, it is impossible for anyone except Pfizer to know what manufacturing process is used, as I have corrected the record here many many time, the patents refer to melt extrusion as but one example of manufacturing methods. Next.
LOL LOL serious breach of engineering principles??? LOL LOL hysterically funny. Elite (not even employing the inventor of their technology) and certainly not having any galenical though leaders is going to tech Pfizer how to do it correctly. LOL LOL This is so hysterically funny that I do not even know where to start. But hey. let me ask, how many patents does the CURRENT staff of this magical company have? That should be good for a few more laughs.
Unfortunately Pfizer no longer has their Elite Central Engineering staff that would have caught this serious breach of engineering principles before deciding to pay the $3.6 bil to acquire Alpharma/king. Pfizer with serious patent expirations has resorted these past 10 yrs to becoming an "acquisition" company thereby giving up "original discovery" new technology. Hundreds of key R&D personnel have been terminated.
It is sad to watch the proud Pfizer deteriorate. However when one picks an Accountant type to lead a Pharma the inevitable happens in terrible cost cutting decisions. "Penny wise Pound Foolish"
http://www.pfizer.com/about/leadership_and_st...an_c__read
Sounds like a bunch of loser companies.
Quote:
Pfizer/Alpharma/King
rfwelsh If you read my past posts on Purdue/Pfizer hot melt extrusion technology thru their patents that would help you to understand better. It is an extremely difficult engineering technology which Purdue never went forward with knowing that it would fail
Strangely Alpharma/King copied the original Purdue and were nailed by a Purdue lawsuit that forced Pfizer to pay royalties to Purdue.
Pfizer/Alpharma/King has already spent 4 years unsuccessfully to try and correct the heat and mechanical extrusion forces from seriously damaging the ER agonist polymer and the antagonist sequestering polymer which is the crux of the problem.
Because Nasrat didn't release the name of the valuation firm. But we will get to $2.10 eventually and even higher.
